{
  "id": 2059431,
  "title": "Samyang Biopharm Hits Daily Limit After mRNA Cancer Vaccine Delivery Study Gains Attention",
  "url": "https://urgent.news/2026/08/20/samyang-biopharm-hits-daily-limit-after-mrna-cancer-vaccine-delivery",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-20T02:46:50.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=275134"
  },
  "original_language": "en",
  "account": null,
  "summary": "Samyang Biopharm's stock hit its daily limit on Aug. 20 following the publication of preclinical research on its proprietary mRNA cancer vaccine delivery platform, NanoReady. The stock rose by 29.79% from the previous session, trading at 56,200 won ($40) as of 9:34 a.m. The positive attention was further fueled by Moderna's announcement of positive Phase 3 results for an mRNA-based cancer treatment. Samyang Biopharm's NanoReady, a nanoparticle-based delivery vehicle, selectively delivers mRNA to dendritic cells in the spleen, which play a crucial role in the immune response. The study, published in the Journal of Controlled Release, demonstrated NanoReady's potential for use in personalized mRNA cancer vaccines, with the added benefit of being able to carry about 20 times more mRNA per particle than conventional lipid nanoparticles.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}